Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Safety and feasibility of autologous adipose-derived stromal vascular fraction in the treatment of keloids: a phase one randomized controlled pilot trial.

Mbiine R., Kayiira A., Wayengera M., Guyton MI., Kiwanuka N., Alenyo R.

Clinical Trial with a reported sample of 8 on Scar, published in Am J Stem Cells (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Am J Stem Cells (2023)
Country
United States
Reported sample size
8
Source database
PubMed
PMID
37215278
PMCID
PMC10195396
DOI
10.21203/rs.3.rs-940210/v1
NCT
NCT04553159
Citations
5

Abstract (original English)

Abstract Autologous adipose-derived stromal vascular fraction (SVF) is described as a therapeutic alternative in keloid treatment. However, most conclusions are based on observational with the majority conducted in high-income countries and yet the highest-burden of keloids is in Low-and middle-income countries (LMICs). In order to explore the therapeutic benefits of SVF in keloids, the safety and feasibility of their use in LMICs need to be evaluated. Methods: In this phase 1 randomized controlled pilot clinical trial conducted in the Plastic Surgery Unit of Kirruddu National Referral Hospital Kampala, 8 patients were assigned 1:1 ratio into either SVF or Triamcinolone Acetonide (TAC) arms. In the SVF arm, a median (IQR) number of stromal cell infiltration of 2.7x10 6 (11x10 6 ) was administered while the controls received 10mg/ml TAC in a ratio of 1:1 TAC into keloid volume. Primary end-points were adverse events development based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 tool and Feasibility assessment based on ≥70% recruitment feasibility and ≥80% interventional feasibility rates. Results: Participant mean age was 27.9 (±6.5) years with a female predilection of 5(63%). Overall, no adverse events were reported in the SVF arm while an ulceration in a single patient in the TAC arm which was a grade II adverse event was reported. Recruitment feasibility

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research